Over 105 years after insulin’s groundbreaking discovery transformed Type 1 diabetes from a fatal diagnosis into a manageable chronic condition, millions worldwide still cannot access this life-saving treatment. The 1921 breakthrough by Frederick Banting and colleagues at the University of Toronto revolutionized diabetes care, yet today approximately 8.4 million people living with Type 1 diabetes face significant barriers to consistent insulin therapy.
Despite its designation as an essential medicine by the World Health Organization, insulin accessibility remains severely compromised across low- and middle-income countries. Complex supply chain disruptions, manufacturing constraints, and economic barriers continue to prevent effective diabetes management for vulnerable populations globally. This persistent access crisis underscores a critical gap between medical innovation and equitable healthcare delivery—a challenge that demands urgent attention from policymakers, healthcare systems, and international health organizations.
Read the full article on GMJ Newsroom.
Was this article helpful?
GMJ Brief · Announcement
📰 Read the full article: Insulin Remains Inaccessible to Millions Despite Century of Progress →
